Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Average Recommendation of “Buy” by Analysts

Posted by Stanley Muller on Sep 13th, 2026

Inventiva S.A. Sponsored ADR (NASDAQ:IVA – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, six have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $15.3750.

A number of equities research analysts have recently weighed in on the company. Cantor Fitzgerald began coverage on Inventiva in a report on Friday, July 17th. They set an “overweight” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th.

Read Our Latest Stock Analysis on Inventiva

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Creative Planning bought a new stake in shares of Inventiva during the second quarter valued at about $32,000. Commonwealth Equity Services LLC lifted its holdings in Inventiva by 19.6% in the fourth quarter. Commonwealth Equity Services LLC now owns 77,561 shares of the company’s stock worth $361,000 after purchasing an additional 12,704 shares during the period. Virtu Financial LLC bought a new position in Inventiva in the 4th quarter valued at about $60,000. XTX Topco Ltd bought a new position in Inventiva in the 4th quarter valued at about $84,000. Finally, NewEdge Advisors LLC acquired a new position in Inventiva during the 3rd quarter valued at about $116,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Stock Performance

NASDAQ IVA opened at $4.02 on Friday. Inventiva has a 52 week low of $3.35 and a 52 week high of $7.98. The company has a 50-day moving average price of $4.58 and a two-hundred day moving average price of $4.96.

About Inventiva

(Get Free Report)

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.